MedPath

ONTRUZANT

ONTRUZANT

Approved
DIN Number

02524325

Drug Class

Human

Market Date

Jul 20, 2022

Company
HC

Samsung Bioepis Co., Ltd.

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02524325
AIG Number0154252001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D ,  Prescription
A
ATC Code
L01FD01 TRASTUZUMAB
Product Specifications
Dosage FormPowder For Solution
Route of AdministrationIntravenous
AHFS Classification10:00.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

TRASTUZUMABActive
Strength: 440 MG / VIAL
Monograph: TRASTUZUMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.